EA200300336A1 - Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич - Google Patents

Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич

Info

Publication number
EA200300336A1
EA200300336A1 EA200300336A EA200300336A EA200300336A1 EA 200300336 A1 EA200300336 A1 EA 200300336A1 EA 200300336 A EA200300336 A EA 200300336A EA 200300336 A EA200300336 A EA 200300336A EA 200300336 A1 EA200300336 A1 EA 200300336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
peptides
vaccine compositions
antibodies induced
detecting antibodies
Prior art date
Application number
EA200300336A
Other languages
English (en)
Other versions
EA006308B1 (ru
Inventor
Биргер Сёренсен
Original Assignee
Бионор Иммуно Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионор Иммуно Ас filed Critical Бионор Иммуно Ас
Publication of EA200300336A1 publication Critical patent/EA200300336A1/ru
Publication of EA006308B1 publication Critical patent/EA006308B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение охватывает новые и модифицированные пептиды, способные индуцировать специфический иммунный ответ к ВИЧ-1, не подавляя активность цитотоксических Т-клеток, с целью получения эффективной профилактической и терапевтической вакцины против ВИЧ. В основе пептидов лежат консервативные участки белков gag p17 и p24 вируса ВИЧ. Описаны антигены в свободной или связанной с носителем форме, включающие, по меньшей мере, один из указанных пептидов, вакцинные композиции, содержащие, по меньшей мере, один из антигенов, наборы для иммуноанализа и способ обнаружения антител, индуцируемых ВИЧ или ВИЧ-специфичными пептидами, с помощью таких антигенов.Отчет о международном поиске был опубликован 2002.06.13.
EA200300336A 2000-09-04 2001-09-03 Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич EA006308B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
PCT/NO2001/000362 WO2002020554A2 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines

Publications (2)

Publication Number Publication Date
EA200300336A1 true EA200300336A1 (ru) 2003-08-28
EA006308B1 EA006308B1 (ru) 2005-10-27

Family

ID=19911533

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300336A EA006308B1 (ru) 2000-09-04 2001-09-03 Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич

Country Status (20)

Country Link
US (2) US7009037B2 (ru)
EP (2) EP1878742A3 (ru)
JP (2) JP2004508381A (ru)
CN (2) CN1282656C (ru)
AR (2) AR033998A1 (ru)
AT (1) ATE406380T1 (ru)
AU (3) AU8270601A (ru)
BR (1) BR0114036A (ru)
CA (1) CA2421193A1 (ru)
DE (1) DE60135564D1 (ru)
EA (1) EA006308B1 (ru)
ES (1) ES2312465T3 (ru)
HK (1) HK1059940A1 (ru)
HU (1) HUP0303134A3 (ru)
MY (1) MY136081A (ru)
NO (1) NO314588B1 (ru)
NZ (2) NZ535148A (ru)
SK (1) SK287917B6 (ru)
WO (1) WO2002020554A2 (ru)
ZA (1) ZA200301740B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
JP5021649B2 (ja) * 2005-08-26 2012-09-12 ノヴォ ノルディスク アクティーゼルスカブ 高分子システムを変性する方法
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
MX2014014683A (es) * 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2017123918A1 (en) 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositons for the activation of gamma-delta t-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
KR20190136048A (ko) 2017-04-03 2019-12-09 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556A (en) * 2021-09-02 2023-03-15 113 Botanicals Ltd Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) * 1991-06-13 1991-06-13 Replico Medical Ab Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
WO1998029551A1 (en) 1997-01-02 1998-07-09 Universidade Federal De Minas Gerais THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1)
GB9703802D0 (en) 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) * 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Also Published As

Publication number Publication date
HUP0303134A3 (en) 2012-09-28
JP2004508381A (ja) 2004-03-18
AU2007202739A1 (en) 2007-07-05
HUP0303134A2 (hu) 2005-03-29
ES2312465T3 (es) 2009-03-01
EP1878742A3 (en) 2008-04-30
EP1322665A2 (en) 2003-07-02
MY136081A (en) 2008-08-29
SK287917B6 (sk) 2012-03-02
CA2421193A1 (en) 2002-03-14
DE60135564D1 (de) 2008-10-09
WO2002020554A3 (en) 2002-06-13
AR071262A2 (es) 2010-06-09
NO20004413L (no) 2002-03-05
AU2001282706B2 (en) 2007-03-22
NZ535148A (en) 2007-06-29
CN101104636A (zh) 2008-01-16
JP2011219481A (ja) 2011-11-04
US7612168B2 (en) 2009-11-03
SK4022003A3 (en) 2003-09-11
NZ524556A (en) 2005-01-28
WO2002020554A2 (en) 2002-03-14
US7009037B2 (en) 2006-03-07
NO20004413D0 (no) 2000-09-04
CN1282656C (zh) 2006-11-01
AU2007202739B2 (en) 2009-12-03
EP1322665B1 (en) 2008-08-27
US20040115615A1 (en) 2004-06-17
EA006308B1 (ru) 2005-10-27
EP1878742A2 (en) 2008-01-16
NO314588B1 (no) 2003-04-14
AU8270601A (en) 2002-03-22
HK1059940A1 (en) 2004-07-23
BR0114036A (pt) 2003-07-22
AR033998A1 (es) 2004-01-21
US20070237783A1 (en) 2007-10-11
ATE406380T1 (de) 2008-09-15
CN1460111A (zh) 2003-12-03
ZA200301740B (en) 2004-06-21

Similar Documents

Publication Publication Date Title
EA200300336A1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
EA200100943A1 (ru) Вич-пептиды, антигены, вакцинные композиции, набор для иммуноанализа и способ определения вич-индуцированных антител
DI MARZO VERONESE et al. Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
SE8604007L (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
NO169844C (no) Htlv-iii (env)-peptider
RU2004136165A (ru) Способ одновременного обнаружения антигенов и антител против инфекционного микроорганизма
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
Locher et al. Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination
ES2058259T3 (es) Antigenos sinteticos para la deteccion de enfermedad relacionada con sida causada por lav-2.
RU2007108306A (ru) Модифицированные пептиды вич-1 и их применение для обнаружения антител против вич
O'Neil et al. Virus threshold determines disease in SIVsmmPBj14-infected macaques
Chattopadhya et al. Profile of antigen-specific antibody response detectable by western blot in relation to diagnostic criteria for human immunodeficiency virus type-1 (HIV-1) infection
DE59907027D1 (de) Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
Wilson et al. Autologous red cell agglutination test for antibodies to feline immunodeficiency virus
TH62264A (th) Hiv เพพไทด์, แอนติเจน องค์ประกอบวัคซีน, ชุดสำเร็จรูปอิมมูโนแอสเสย์ และวิธีสำหรับตรวจหาแอนติบอดีที่ชักนำโดย hiv
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
Gnann Jr et al. Designing Peptides to Immunologically Distinguish Specific Human Immunodeficiency Virus Isolates
Human JOHN W. GNANN, JR, AND MICHAEL BA OLDSTONE
ES2129358A1 (es) Procedimiento de deteccion en una sola prueba de anticuerpos anti-virus de la hepatitis c, de la inmunodeficiencia humano y antigeno de superficie del virus de la hepatitis b".

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU